Metabolism is the process through which the body generates energy from food. Food comprises biomolecules, including carbohydrates, proteins, and fats. Chemicals in the digestive system are used to break the food into sugars and acids. Metabolic disorders disrupt the normal function of metabolic processes and lead to excess or lack of essential components that are needed to stay healthy. These disorders are either inherited or acquired during the lifetime of an individual.
Factors such as increase in the cases of metabolic disorders, rise in awareness about the availability of therapeutics for metabolic disorders, increase in demand for one-time therapies for metabolic disorders, commencement of patient assistance programs for providing treatment for a range of metabolic disorders, rapid advancements in technology, rise in the prevalence of diabetes and obesity, and initiatives were undertaken by the government are expected to drive the metabolic disorder therapeutics market in the coming years. However, low compliance and adherence rates for metabolic disorder therapies and the availability of alternative options for treatment are expected to hinder the metabolic disorder therapeutics market during the forecast period.
According to the American Diabetes Association, in 2015, approximately 30.3 million Americans, or about 9.4% of the population, suffered from diabetes. In the U.S., about 1.25 million children and adults have type 1 diabetes.
According to the World Health Organization (WHO), the global prevalence of diabetes among adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014. The prevalence of diabetes has been rising more steadily in middle- and low-income countries.
According to the World Health Organization (WHO), in 2016, globally more than 1.9 billion adults aged 18 years and older were categorized as overweight. Out of these, over 650 million were categorized as obese.
According to the Centers for Disease Control and Prevention (CDC), having increased blood cholesterol puts people at risk of heart disease, and it is considered to be the leading cause of death in the U.S. The risk of heart disease for people with high cholesterol is about twice as high compared to that for people with low cholesterol. Approximately 71 million adults in the U.S. are estimated to have high low-density lipoproteins (LDL) or bad cholesterol. About 7% of children and adolescents between the ages of 6 and 19 have high total cholesterol. High cholesterol has no symptoms. Therefore, many people do not know about their high cholesterol level. A simple blood test can be used to check the cholesterol level of a person.
The metabolic disorder therapeutics market can be segmented based on disease, product, and region. In terms of disease, the metabolic disorder therapeutics market can be divided into lysosomal storage disease, diabetes, obesity, and hypercholesterolemia. The diabetes segment is anticipated to dominate the market because of the extensive use of metabolic disease therapies in anti-diabetic injections and drugs and injections for controlling the blood sugar levels. Based on product, the metabolic disorder therapeutics market can be classified into metachromatic leukodystrophy, hepatic encephalopathy, globoid leukodystrophy, and others.
In terms of region, the metabolic disorder therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the metabolic disorder therapeutics market, due to the presence of key players, rise in prevalence of diabetes and obesity, well-developed health care infrastructure, and increase in health care expenditure. The metabolic disorder therapeutics market in the Asia Pacific is expected to expand at a rapid pace. Increase in patient population, rise in economic development, increase in government initiatives, and rise in awareness are factors propelling the metabolic disorder therapeutics market in the Asia Pacific.
Key players operating in the global metabolic disorder therapeutics market are Sanofi, Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca, Amgen Inc., Merck KGaA, Actelion Pharmaceuticals Ltd, Biocon, and AbbVie Inc. For gaining a competitive advantage in the metabolic disorder therapeutics market, there is active involvement of key players in different growth strategies such as partnerships, collaborations, agreements, and new product development.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.